Lantheus Holdings, Inc (LNTH) Dividend History

Company News

• Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

  Lantheus has successfully acquired Life Molecular Imaging and appointed Dr. Ludger Dinkelborg as Head of R&D. The acquisition includes Neuraceq®, an FDA-approved PET imaging agent for Alzheimer's disease detection, and provides Lantheus with advanced R&D capabilities and international presence.

  GlobeNewswire Inc.
• Lantheus' Pylarify Hit $1B in 2024 Sales

  Lantheus Holdings reported strong Q4 and full-year 2024 results, with its prostate imaging drug Pylarify becoming a blockbuster. The company also announced two strategic acquisitions to expand its radiopharmaceutical capabilities. Definity maintained its market leadership in ultrasound-enhancing agents.

  The Motley Fool
• Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio

  Lantheus Holdings agreed to acquire Evergreen Theragnostics for $250 million upfront, plus up to $752.5 million in milestone payments, to expand its oncology diagnostic pipeline. The acquisition also adds Neuraceq, an Alzheimer's diagnostic, to Lantheus' portfolio.

  Benzinga
• Here's Why Investors Must Hold on to Centene (CNC) Stock Now

  Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.

  Zacks Investment Research

  Featured Companies: BVS CNC EHC